Showing results (91-100 of 186) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk LymphomaRyan D Cassaday, Oliver W Press, John M Pagel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2019
Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant WithdrawalAng Li, Qian Wu, Chris Davis, et al.
Leukemia & Lymphoma|December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacyAjay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 24, 2025
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell LymphomaCarrie Ho, Neena Kennedy, Mengyang Di, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2016
Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for LymphomaSolomon A Graf, Jennifer E Vaughn, Thomas R Chauncey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 4, 2011
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantationRon Ram, Ted A Gooley, David G Maloney, et al.
Leukemia & Lymphoma|June 29, 2010
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumAjay K Gopal, Oliver W Press, Andrei R Shustov, et al.
Cancer Causes & Control : CCC|January 17, 2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access interventionKristine A Karvonen, Jean A McDougall, Sarah D Hohl, et al.
British Journal of Haematology|January 6, 2017
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphomaAndrew J Cowan, Phillip A Stevenson, Ted A Gooley, et al.
Pageof 19